This analysis reveals the impact of smoking on clozapine metabolism in individuals with treatment-resistant schizophrenia, suggesting significant clinical implications.
The atypical antipsychotic clozapine is uniquely efficacious in addressing treatment‐resistant schizophrenia. There are significant variations, however, in its pharmacokinetic profile among treated patients, resulting from altered metabolic capacity secondary to drug‐drug interaction and/or smoking status (Haring et al., 1989). Smoking cigarettes produces chemicals that act as potent inducers of the activity of CYP1A2, the primary enzyme responsible for the metabolism of clozapine to the active metabolite norclozapine.
No takes yet. Share an insight, caveat, or question.
Y. W. Francis Lam (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: